Dr. Steven C. Quay, President, and CEO of Atossa stated, “IRB approval was the final step in making our oral Endoxifen available to this patient. We are encouraged that the regulatory authorities recognize the potential for additional treatment options for pre-menopausal breast cancer patients. The impact of our proprietary oral Endoxifen on this patient’s tumor during the pre-surgical treatment window is consistent with research by others, and strongly supports the continued development of our proprietary oral Endoxifen.”What is “FDA Expanded Access?” Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. For more information about this process, please see the FDA website: FDA Expanded Use Website More on Atossa’s Proprietary Endoxifen in Breast Cancer Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Studies by others have shown that breast cancer patients with endoxifen levels of 30 nM and above have a lower risk for developing future breast cancer. Up to half of the patients taking tamoxifen do not produce therapeutic levels of endoxifen, frequently because of limited liver metabolism capability. Studies by others indicate that endoxifen’s molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens, including fulvestrant. Pathway analysis of differentially regulated genes revealed substantial differences related to endoxifen concentrations including significant induction of cell cycle arrest and markers of apoptosis following treatment with high, but not low, concentrations of endoxifen. Many patients taking tamoxifen eventually stop responding, becoming tamoxifen refractory. In a small study by others of oral endoxifen use by tamoxifen-refractory patients, endoxifen provided an acceptable safety profile and promising antitumor activity. Another class of drugs called aromatase inhibitors is also frequently used to treat breast cancer. However, they are not FDA-approved for use in pre-menopausal women and can only be given to pre-menopausal women in conjunction with drugs for ovarian suppression/oblation, which can cause cardiovascular and other toxicities. Additionally, 20-30 percent of those taking aromatase inhibitors may experience fractures, bone pain or osteoporosis. Because of these potential advantages, Atossa is developing oral and topical forms of Endoxifen.
Institutional Review Board Approves Use of Atossa’s Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) (“Atossa”) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Shares of Atossa jumped to a high of $4.865 today and are currently trading at $4.14 up 8.43% on 6.84 Million shares of trading. This move of Atossa’s shares came about post their announcement before the market’s open on Tuesday that the Institutional Review Board (IRB) had approved the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. This IRB approval follows the FDA’s recent “safe to proceed” letter and permits Atossa’s oral Endoxifen to be provided to the patient. Under the FDA expanded access IND program, the use of Atossa’s proprietary oral Endoxifen is restricted solely to this patient.